Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
210.01
+3.36 (1.63%)
At close: Nov 26, 2025, 4:00 PM EST
212.50
+2.49 (1.19%)
After-hours: Nov 26, 2025, 7:09 PM EST
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 213.63M EUR in the quarter ending September 30, 2025, with 269.40% growth. This brings the company's revenue in the last twelve months to 646.55M, up 97.46% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
646.55M EUR
Revenue Growth
+97.46%
P/S Ratio
16.68
Revenue / Employee
635,740 EUR
Employees
1,017
Market Cap
12.83B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ASND News
- 2 days ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters
- 2 days ago - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewsWire
- 10 days ago - Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics - GlobeNewsWire
- 15 days ago - Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Ascendis Pharma Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 15 days ago - Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
- 20 days ago - New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism - GlobeNewsWire
- 22 days ago - Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - GlobeNewsWire